CLAIMS

1. A pharmaceutical formulation in the form of a tablet comprising *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine, microcrystalline cellulose (MCC) and dicalcium phosphate anhydrous (DCPA), wherein the mass ratio of MCC to DCPA is from 3:1 to 2:3.

2. A pharmaceutical formulation in the form of a tablet according to claim 1, wherein the mass ratio of MCC to DCPA is from 3:1 to 3:2.

3. A pharmaceutical formulation in the form of a tablet according to claim 1 or claim 2, wherein the tablet is an immediate release tablet.

4. A pharmaceutical formulation in the form of a tablet according to any preceding claim, wherein the amount of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine is up to 60% w/w.

5. A pharmaceutical formulation in the form of a tablet according to any preceding claim, wherein the amount of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine is 27% w/w.

6. A pharmaceutical formulation in the form of a tablet according to any preceding claim, wherein the combined amount of MCC and DCPA is from 15% w/w to 85% w/w.

7. A pharmaceutical formulation in the form of a tablet according to any preceding claim, wherein the combined amount of MCC and DCPA is from 40% w/w to 85% w/w.

8. A pharmaceutical formulation in the form of a tablet according to any preceding claim, further comprising at least one additional disintegrant in an amount of up to 10% w/w, optionally wherein the disintegrant is selected from croscarmellose sodium, crospovidine and sodium starch glycolate.

9. A pharmaceutical formulation in the form of a tablet according to claim 8, wherein the at least one additional disintegrant is sodium starch glycolate.

10. A pharmaceutical formulation in the form of a tablet according to claim 8 or claim 9, wherein the at least one additional disintegrant is present in an amount of up to 5% w/w.

11. A pharmaceutical formulation in the form of a tablet according to any preceding claim, further comprising at least one lubricant in an amount of up to 4% w/w, optionally wherein the lubricant is selected from magnesium stearate, calcium stearate and sodium stearyl fumarate (SSF).

12. A pharmaceutical formulation in the form of a tablet according to claim 11, wherein the at least one lubricant is magnesium stearate.

13. A pharmaceutical formulation in the form of a tablet according to claim 11 or claim 12, wherein the at least one lubricant is present in an amount of up to 1.5% w/w.

14. A pharmaceutical formulation in the form of a tablet according to any preceding claim containing 25 mg, 50 mg or 100 mg of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine.

15. A process for manufacturing a pharmaceutical formulation in the form of a tablet according to any of claims 1 to 14 comprising the steps of:
i) dry granulating *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine with MCC and DCPA to form a blend; and
ii) compressing the blend into a tablet.

16. A process according to claim 15 wherein the process comprises roller compaction.

17. A process according to claim 15 or claim 16, wherein the process comprises a continuous direct compression process.